EP3546461
7-bensýl-4-(2-metýlbensýl)-2,4,6,7,8,9-hexahýdróimídasó[1,2-a]pýrídó[3,4-e]pýrímídín-5(1H)-ón, sölt þar af og aðferðir við að nota það í samsettri meðferð
:
EP einkaleyfi í gildi á Íslandi:
12.9.2014:
11.8.2021:
19158371.5
:
7.10.2021:
15.11.2021
:
11.9.2034:
11.9.2025:
30.9.2025
:
7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY
12.9.2014
11.8.2021
7.10.2021
15.11.2021
11.9.2025
:
Oncoceutics, Inc.:
3675 Market Street Suite 200, Philadelphia, PA 19104, US
:
STOGNIEW, Martin:
Blue Pell, PA 19422, US
:
ALLEN, Joshua E.:
New Haven, CT 06511, US
:
POTTORF, Richard S.:
Indianapolis, IN 46526, US
:
NALLAGANCHU, Bhaskara Rao:
Hillsborough, NJ 08852, US
:
OLSON, Gary L.:
Mountainside, NJ 07092, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
201361904718 P:
15.11.2013:
US
:
201414208657:
13.3.2014:
US
:
201414341392:
25.7.2014:
US
:
PCT/US2014/048241:
25.7.2014:
WO
:
C07D 471/14, A61K 31/519, A61K 31/44, A61K 45/06, A61P 35/00
: 8
: 13.9.2021
: 11.9.2022
: Sigurjónsson & Thor ehf.
: 9
: 19.8.2022
: 11.9.2023
: Patice ehf.
: 10
: 28.8.2023
: 11.9.2024
: Árnason Faktor ehf.
: 11
: 22.8.2024
: 11.9.2025
: Árnason Faktor ehf.